Tags

Type your tag names separated by a space and hit enter

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.
Blood. 2011 Apr 21; 117(16):4190-207.Blood

Abstract

Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the American Society of Hematology published a landmark guidance paper designed to assist clinicians in the management of this disorder. Since 1996 there have been numerous advances in the management of both adult and pediatric ITP. These changes mandated an update in the guidelines. This guideline uses a rigorous, evidence-based approach to the location, interpretation, and presentation of the available evidence. We have endeavored to identify, abstract, and present all available methodologically rigorous data informing the treatment of ITP. We provide evidence-based treatment recommendations using the GRADE system in those areas in which such evidence exists. We do not provide evidence in those areas in which evidence is lacking, or is of lower quality--interested readers are referred to a number of recent, consensus-based recommendations for expert opinion in these clinical areas. Our review identified the need for additional studies in many key areas of the therapy of ITP such as comparative studies of "front-line" therapy for ITP, the management of serious bleeding in patients with ITP, and studies that will provide guidance about which therapy should be used as salvage therapy for patients after failure of a first-line intervention.

Authors+Show Affiliations

University of Texas, Southwestern Medical Center, Dallas, TX, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Practice Guideline
Review

Language

eng

PubMed ID

21325604

Citation

Neunert, Cindy, et al. "The American Society of Hematology 2011 Evidence-based Practice Guideline for Immune Thrombocytopenia." Blood, vol. 117, no. 16, 2011, pp. 4190-207.
Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-207.
Neunert, C., Lim, W., Crowther, M., Cohen, A., Solberg, L., & Crowther, M. A. (2011). The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, 117(16), 4190-207. https://doi.org/10.1182/blood-2010-08-302984
Neunert C, et al. The American Society of Hematology 2011 Evidence-based Practice Guideline for Immune Thrombocytopenia. Blood. 2011 Apr 21;117(16):4190-207. PubMed PMID: 21325604.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. AU - Neunert,Cindy, AU - Lim,Wendy, AU - Crowther,Mark, AU - Cohen,Alan, AU - Solberg,Lawrence,Jr AU - Crowther,Mark A, AU - ,, Y1 - 2011/02/16/ PY - 2011/2/18/entrez PY - 2011/2/18/pubmed PY - 2011/7/14/medline SP - 4190 EP - 207 JF - Blood JO - Blood VL - 117 IS - 16 N2 - Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the American Society of Hematology published a landmark guidance paper designed to assist clinicians in the management of this disorder. Since 1996 there have been numerous advances in the management of both adult and pediatric ITP. These changes mandated an update in the guidelines. This guideline uses a rigorous, evidence-based approach to the location, interpretation, and presentation of the available evidence. We have endeavored to identify, abstract, and present all available methodologically rigorous data informing the treatment of ITP. We provide evidence-based treatment recommendations using the GRADE system in those areas in which such evidence exists. We do not provide evidence in those areas in which evidence is lacking, or is of lower quality--interested readers are referred to a number of recent, consensus-based recommendations for expert opinion in these clinical areas. Our review identified the need for additional studies in many key areas of the therapy of ITP such as comparative studies of "front-line" therapy for ITP, the management of serious bleeding in patients with ITP, and studies that will provide guidance about which therapy should be used as salvage therapy for patients after failure of a first-line intervention. SN - 1528-0020 UR - https://www.unboundmedicine.com/medline/citation/21325604/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-4971(20)45231-0 DB - PRIME DP - Unbound Medicine ER -